

Manal F Abdelmalek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4790115/publications.pdf>

Version: 2024-02-01

143
papers

20,542
citations

13865

67
h-index

10734

138
g-index

145
all docs

145
docs citations

145
times ranked

16665
citing authors

#	ARTICLE	IF	CITATIONS
1	Perceptions of Exercise and Its Challenges in Patients With Nonalcoholic Fatty Liver Disease: A Survey-Based Study. <i>Hepatology Communications</i> , 2022, 6, 334-344.	4.3	12
2	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	7.3	45
3	Liver Mass: Thinking out-of-the box. <i>Gastroenterology</i> , 2022, , .	1.3	0
4	Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children. <i>Epigenetics</i> , 2022, 17, 1446-1461.	2.7	4
5	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	3.7	9
6	Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 603-616.	8.1	40
7	Validation of the accuracy of the FASTâ„¢ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859.	2.5	20
8	PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference. <i>Hepatology</i> , 2022, 76, 1778-1793.	7.3	10
9	Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1267-1274.e1.	4.4	25
10	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 24-39.	17.8	174
11	REPLY:. <i>Hepatology</i> , 2021, 73, 1625-1625.	7.3	0
12	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 274-282.	3.7	34
13	Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations. <i>Hepatology</i> , 2021, 73, 1199-1206.	7.3	16
14	Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 13-13.	3.0	13
15	Insights Into Metabolic Mechanisms and Their Application in the Treatment of NASH. <i>Clinical Liver Disease</i> , 2021, 17, 29-32.	2.1	4
16	Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 608-617.	4.3	15
17	Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. <i>ESC Heart Failure</i> , 2021, 8, 842-848.	3.1	24
18	The role of bariatric surgery in the management of nonalcoholic steatohepatitis. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 208-215.	2.3	11

#	ARTICLE	IF	CITATIONS
19	The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Contemporary Clinical Trials</i> , 2021, 104, 106335.	1.8	38
20	Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2021, 74, 1220-1233.	7.3	54
21	Epithelia-Sensory Neuron Cross Talk Underlies Cholestatic Itch Induced by Lysophosphatidylcholine. <i>Gastroenterology</i> , 2021, 161, 301-317.e16.	1.3	57
22	A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. <i>Hepatology</i> , 2021, 74, 3146-3160.	7.3	25
23	Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 623-633.	3.7	28
24	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	1.3	229
25	Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD. <i>Hepatology Communications</i> , 2021, 5, 598-607.	4.3	12
26	Nonalcoholic fatty liver disease: another leap forward. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 85-86.	17.8	89
27	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. <i>American Journal of Gastroenterology</i> , 2021, 116, 254-262.	0.4	65
28	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558.	27.0	284
29	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 918-932.	4.1	41
30	Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. <i>Liver Transplantation</i> , 2020, 26, 68-79.	2.4	26
31	Succinate GPR111 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation. <i>Liver International</i> , 2020, 40, 830-843.	3.9	34
32	Geniviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	1.8	92
33	Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 1-21.	4.5	58
34	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. <i>Journal of Hepatology</i> , 2020, 72, 885-895.	3.7	107
35	Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2020, 158, 1334-1345.e5.	1.3	203
36	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	1.3	1,840

#	ARTICLE	IF	CITATIONS
37	Genecriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	7.3	227
38	Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	7.3	79
39	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. <i>Journal of Hepatology</i> , 2020, 73, 680-693.	3.7	69
40	Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3413-3430.	2.3	10
41	PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. <i>Molecular Metabolism</i> , 2019, 29, 99-113.	6.5	20
42	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	7.3	226
43	Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1867-1876.e3.	4.4	31
44	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1877-1885.e5.	4.4	145
45	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. <i>Hepatology</i> , 2019, 70, 1457-1469.	7.3	547
46	A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. <i>Hepatology Communications</i> , 2019, 3, 1571-1584.	4.3	16
47	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	13.7	818
48	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019, 114, 1626-1635.	0.4	65
49	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2.	4.4	322
50	Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, 735-744.	3.7	60
51	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2019, 156, 88-95.e5.	1.3	73
52	Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. <i>Journal of Hepatology</i> , 2019, 70, 133-141.	3.7	149
53	Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 924-932.	3.9	47
54	Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury. <i>Journal of Clinical Investigation</i> , 2019, 129, 5278-5293.	8.2	26

#	ARTICLE	IF	CITATIONS
55	NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018, 391, 1174-1185.	13.7	338
56	Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 68, 1063-1075.	3.7	617
57	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1684.	4.4	0
58	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	7.3	125
59	Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018, 67, 134-144.	7.3	192
60	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	7.3	528
61	Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2018, 2, 1344-1355.	4.3	58
62	Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>Lancet, The</i> , 2018, 392, 2705-2717.	13.7	374
63	Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study. <i>PLoS ONE</i> , 2018, 13, e0204308.	2.5	17
64	Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1428-1435.e2.	1.3	55
65	Whole-Exome Sequencing Study of Extreme Phenotypes of NAFLD. <i>Hepatology Communications</i> , 2018, 2, 1021-1029.	4.3	8
66	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	1.3	253
67	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. <i>Hepatology</i> , 2018, 68, 1646-1648.	7.3	1
68	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370.	3.7	51
69	De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017, 21, 321-335.	2.1	23
70	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. <i>Journal of Pediatrics</i> , 2017, 187, 141-146.e1.	1.8	91
71	Reply to Kim et al.. <i>American Journal of Gastroenterology</i> , 2017, 112, 807-808.	0.4	0
72	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 127-131.e2.	4.4	66

#	ARTICLE	IF	CITATIONS
73	Exercise Training as Treatment of Nonalcoholic Fatty Liver Disease. <i>Journal of Functional Morphology and Kinesiology</i> , 2017, 2, 35.	2.4	10
74	Systematic transcriptome analysis reveals elevated expression of alcoholâ€metabolizing genes in <scp>NAFLD</scp> livers. <i>Journal of Pathology</i> , 2016, 238, 531-542.	4.5	40
75	Nonalcoholic Fatty Liver Disease. <i>North Carolina Medical Journal</i> , 2016, 77, 216-219.	0.2	6
76	Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis. <i>American Journal of Gastroenterology</i> , 2016, 111, 1591-1598.	0.4	43
77	The clinical and economic burden of NAFLD: time to turn the tide. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 685-686.	17.8	19
78	A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 64, 85-91.	7.3	128
79	Elafibranor, an Agonist of the Peroxisome Proliferatorâ€Activated Receptorâ€Î± andâ€Î³, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	1.3	847
80	Treatment response in the PIVENS trial is associated with decreased hedgehog pathway activity. <i>Hepatology</i> , 2015, 61, 98-107.	7.3	63
81	Reply. <i>Hepatology</i> , 2015, 61, 1770-1771.	7.3	0
82	Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2015, 62, 165-175.	3.0	128
83	Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 1948-1957.	1.5	40
84	Sugar sweetened beverages and fatty liver disease: Rising concern and call to action. <i>Journal of Hepatology</i> , 2015, 63, 306-308.	3.7	5
85	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2015, 385, 956-965.	13.7	1,840
86	Repair-Related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism. <i>Endocrinology</i> , 2014, 155, 4591-4601.	2.8	53
87	Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014, 59, 1406-1414.	7.3	250
88	Analyzing the impact of increasing Mechanical Index (MI) and energy deposition on shear wave speed (SWS) reconstruction in human liver. , 2014, , .		0
89	Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014, 59, 471-482.	7.3	256
90	No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial. <i>Gastroenterology</i> , 2014, 147, 377-384.e1.	1.3	260

#	ARTICLE	IF	CITATIONS
91	Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2013, 145, 1076-1087.	1.3	340
92	IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients. <i>Journal of Hepatology</i> , 2013, 58, 402-403.	3.7	13
93	High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. <i>Hepatology</i> , 2013, 58, 1632-1643.	7.3	249
94	Genetic signatures in choline and 1â€carbon metabolism are associated with the severity of hepatic steatosis. <i>FASEB Journal</i> , 2013, 27, 1674-1689.	0.5	40
95	Hedgehog pathway and pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013, 57, 1814-1825.	7.3	60
96	Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. <i>Liver International</i> , 2013, 33, 1062-1070.	3.9	123
97	NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2012, 61, 1323-1329.	12.1	231
98	Association Between Puberty and Features of Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 786-794.	4.4	74
99	Reply to: The use of acoustic radiation force-based shear stiffness in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012, 56, 996.	3.7	4
100	Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. <i>Human Pathology</i> , 2012, 43, 790-800.	2.0	70
101	Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 1711-1721.	7.3	185
102	Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. <i>Hepatology</i> , 2012, 56, 952-960.	7.3	150
103	Sirolimus Conversion Regimen Versus Continued Calcineurin Inhibitors in Liver Allograft Recipients: A Randomized Trial. <i>American Journal of Transplantation</i> , 2012, 12, 694-705.	4.7	104
104	A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2012, 55, 419-428.	7.3	141
105	Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2011, 55, 666-672.	3.7	318
106	Increased production of sonic hedgehog by ballooned hepatocytes. <i>Journal of Pathology</i> , 2011, 224, 401-410.	4.5	150
107	Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 53, 106-115.	7.3	224
108	Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. <i>European Journal of Nutrition</i> , 2010, 49, 1-9.	3.9	83

#	ARTICLE	IF	CITATIONS
109	Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 1961-1971.	7.3	609
110	Reply: Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?. <i>Hepatology</i> , 2010, 51, 1859-1860.	7.3	3
111	Regional Anthropometric Measures and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1062-1069.	4.4	21
112	Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial. <i>Hepatology</i> , 2009, 50, 1818-1826.	7.3	185
113	Hedgehog-Mediated Epithelial-to-Mesenchymal Transition and Fibrogenic Repair in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2009, 137, 1478-1488.e8.	1.3	232
114	Nonalcoholic Fatty Liver Disease in Women. <i>Women's Health</i> , 2009, 5, 191-203.	1.5	110
115	Fructose consumption as a risk factor for non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2008, 48, 993-999.	3.7	718
116	Successful Treatment of Chronic Hepatitis C With Pegylated Interferon, Ribavirin, and Infliximab in a Patient with Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2007, 102, 1333-1334.	0.4	26
117	Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance. <i>Medical Clinics of North America</i> , 2007, 91, 1125-1149.	2.5	136
118	De Novo nonalcoholic fatty liver disease after liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 788-790.	2.4	10
119	Acute Liver Failure Occurring Immediately Following Anti-D Immune Globulin Infusion in a Patient with Chronic Hepatitis B Infection. <i>Digestive Diseases and Sciences</i> , 2007, 52, 914-919.	2.3	4
120	The impact of steatosis and alcohol on hepatitis C. <i>Current Hepatitis Reports</i> , 2007, 6, 39-45.	0.3	0
121	Familial Aggregation of Insulin Resistance in First-Degree Relatives of Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1162-1169.	4.4	74
122	Mechanisms underlying nonalcoholic steatohepatitis. <i>Drug Discovery Today Disease Mechanisms</i> , 2006, 3, 479-488.	0.8	8
123	Betaine Resolves Severe Alcohol-Induced Hepatitis and Steatosis Following Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1226-1229.	2.3	14
124	Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 51-57.	2.4	146
125	Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 754-761.	2.4	32
126	Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis. <i>Liver Transplantation</i> , 2006, 12, 306-309.	2.4	8

#	ARTICLE	IF	CITATIONS
127	A Comparison of Tacrolimus and Cyclosporine in Liver Transplantation: Effects on Renal Function and Cardiovascular Risk Status. <i>American Journal of Transplantation</i> , 2005, 5, 1111-1119.	4.7	83
128	Short Recovery Time After Percutaneous Liver Biopsy: Should We Change Our Current Practices?. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 926-929.	4.4	82
129	Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2004, 10, 199-207.	2.4	135
130	One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2004, 10, 1240-1247.	2.4	146
131	Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. <i>Liver Transplantation</i> , 2003, 9, 1253-1257.	2.4	33
132	Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient. <i>Transplantation</i> , 2003, 75, 730-732.	1.0	12
133	Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. <i>Hepatology</i> , 2003, 38, 859-868.	7.3	126
134	Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. <i>Liver Transplantation</i> , 2002, 8, 1000-1006.	2.4	123
135	Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. <i>American Journal of Gastroenterology</i> , 2001, 96, 2711-2717.	0.4	391
136	<i>Tropheryma whippelii</i> DNA Is Rare in the Intestinal Mucosa of Patients without Other Evidence of Whipple Disease. <i>Annals of Internal Medicine</i> , 2001, 134, 115.	3.9	88
137	Anti[ndash]Interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 1064-1070.	2.4	139
138	Whipple's arthritis: Direct detection of <i>Tropheryma whippelii</i> in synovial fluid and tissue. <i>Arthritis and Rheumatism</i> , 1999, 42, 812-817.	6.7	110
139	Treatment of Chronic Hepatitis C With Interferon With or Without Ursodeoxycholic Acid. <i>Journal of Clinical Gastroenterology</i> , 1998, 26, 130-134.	2.2	17
140	Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. <i>Digestive Diseases and Sciences</i> , 1997, 42, 847-850.	2.3	31
141	Rectal Bleeding from a Mucous Fistula Secondary to a Dieulafoy's Lesion. <i>Journal of Clinical Gastroenterology</i> , 1997, 24, 259-261.	2.2	12
142	Two Cases from the Spectrum of Nonalcoholic Steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 1995, 20, 127-130.	2.2	105
143	79-Year-Old Woman With Blue Toes. <i>Mayo Clinic Proceedings</i> , 1995, 70, 292-295.	3.0	8